Lonafarnib

Eiger BioPharmaceuticals, hepatitis, lonafarnib, liver toxicity, phase 3 trial hold, pipeline, Clinical trial hold

Eiger halts hepatitis drug development after liver toxicity, seeks funding for other programs

Anika Sharma

Eiger BioPharmaceuticals has made the decision to discontinue the pursuit of a home for peginterferon lambda, a drug that was ...

Eiger Implements Workforce Reduction as FDA Raises Standards for Hepatitis Drug

Eiger Implements Workforce Reduction as FDA Raises Standards for Hepatitis Drug

SG Tylor

Source – Eiger BioPharmaceuticals On June 29, 2023 Eiger BioPharmaceuticals announced a reduction in staffing by 25% and a strategic ...